Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 6/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565520 | 1.00 | KCNH2 (0.53) | KCNH2SCN3ACYP2C19DPP4RIPK1 | |
| SCHEMBL20565506 | 1.00 | KCNH2 (0.53) | KCNH2SCN3ACYP2C19DPP4RIPK1 | |
| SCHEMBL20835370 | 0.84 | KCNH2 (0.44) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL7769176 | 0.83 | KCNH2 (0.52) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL7769177 | 0.83 | KCNH2 (0.52) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL7775249 | 0.83 | KCNH2 (0.52) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL7773300 | 0.83 | KCNH2 (0.52) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL2038087 | 0.83 | KCNH2 (0.56) | KCNH2SCN3ACYP2C19DPP4NPC1 | |
| SCHEMBL21093658 | 0.83 | KCNH2 (0.49) | KCNH2SCN3ARIPK1CA1 | |
| SCHEMBL5515868 | 0.83 | KCNH2 (0.52) | KCNH2SCN3ARIPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773249-B | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| EP-3074008-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATION | EPICS THERAPEUTICS (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-20170283376-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2017-10-05 | — | — | US | disclosed |
| EP-2513053-B1 | Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders | OGEDA SA (BE) | 2017-10-04 | — | — | EP | disclosed |
| US-9770435-B2 | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | OGEDA SA (BE) | 2017-09-26 | — | — | US | disclosed |
| US-9695120-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | OGEDA SA (BE) | 2017-07-04 | — | — | US | disclosed |
| US-20160303075-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2016-10-20 | — | — | US | disclosed |
| EP-3074008-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | Euroscreen S.A. (BE) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015078949-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN SA (BE) | 2015-06-04 | — | — | WO | disclosed |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
| EP-2513053-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | Euroscreen S.A. (BE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073376-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885CYP2C19 2088/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885CYP2C19 2088/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | KCNH2 3613/4885SCN3A 2658/4885CYP2C19 1827/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885CYP2C19 2088/4885 |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | KCNH2 3613/4885SCN3A 2658/4885CYP2C19 1827/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KCNH2 2051/4885SCN3A 1653/4885CYP2C19 1992/4885 |
| US-20160303075-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | PTGS1, PTGES, PTGER1 | KCNH2 3364/4885SCN3A 2371/4885CYP2C19 62/4885 |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | KCNH2 2421/4885SCN3A 1512/4885CYP2C19 2056/4885 |
| US-20170283376-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885CYP2C19 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.